Page 19 - Loncode Institute News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Loncode institute. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Loncode Institute Today - Breaking & Trending Today

Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results


Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
News provided by
Share this article
Share this article
- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep s anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
- Preclinical studies show that pelareorep s synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors
- Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021
- Strong financial foundation with over $50 million in cash on hand and cash runway to Q4-2022 ....

United States , Comunidad Autonoma De Cataluna , Matt Coffey , Oncolytic Reovirus Pelareorep , Jon Patton , Timothy Mccarthy , Kols Aleix Prat , Oncolytics Biotech Inc , National Cancer Institute , Company Contact , Loncode Institute , American Association For Cancer Research , Merck Kga , Leiden University Medical Center , Merck Kgaa , Oncolytics Biotech , Breast Cancer Program , Securities Exchange , Roche Group , Chief Executive Officer , American Association , Cancer Research , Annual Meeting , Mayo Clinic , Key Opinion Leaders , Aleix Prat ,

Oncolytics Biotech Reports 2021 First Quarter Development Highlights and Financial Results


Oncolytics Biotech Reports 2021 First Quarter Development Highlights and Financial Results
- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep s anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
- Preclinical studies show that pelareorep s synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors
- Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021
- Strong financial foundation with over $50 million in cash on hand and cash runway to Q4-2022
SAN DIEGO and CALGARY, AB, May 7, 2021 /PRNewswire/ Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended March 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted. ....

United States , Comunidad Autonoma De Cataluna , Matt Coffey , Oncolytic Reovirus Pelareorep , Jon Patton , Timothy Mccarthy , Kols Aleix Prat , Oncolytics Biotech Inc , National Cancer Institute , Company Contact , Loncode Institute , American Association For Cancer Research , Merck Kga , Leiden University Medical Center , Merck Kgaa , Breast Cancer Program , Securities Exchange , Roche Group , Prnewswire Oncolytics Biotech Inc , Chief Executive Officer , Oncolytics Biotech , American Association , Cancer Research , Annual Meeting , Mayo Clinic , Key Opinion Leaders ,